About CanRIO
Canadian Research Group of Rheumatology in Immuno-Oncology
Our Mission
CanRIO (Canadian Research Group of Rheumatology in Immuno-Oncology) is a nationwide network of rheumatologists and researchers dedicated to improving outcomes for patients experiencing rheumatic immune-related adverse events (irAEs) from cancer immunotherapy.
As immune checkpoint inhibitors have revolutionized cancer treatment, they have also introduced new challenges in managing immune-related side effects. CanRIO brings together experts from academic centres across Canada to:
- Advance research into the mechanisms and management of rheumatic irAEs
- Develop clinical guidelines and best practices for diagnosis and treatment
- Provide education for healthcare professionals through accredited learning modules
- Build a prospective cohort to better understand long-term outcomes
- Connect patients with specialists who understand their unique needs
CanRIO at a Glance
PLACEHOLDER: Confirm exact stats with Megan/Faiza
What We Do
Research
We maintain a prospective cohort study tracking patients with rheumatic irAEs, contributing to the global understanding of these conditions.
Education
Our accredited CME modules and learning rounds help physicians stay current on diagnosis and management of rheumatic irAEs.
Clinical Network
We connect patients with rheumatologists who specialize in managing immune-related side effects from cancer treatment.
Cohort Data
Learn about our prospective research cohort
Scientific Advisory Committee
Meet our leadership team
Our Sponsors
Organizations that support our work